Sanofi (SANP.XC)
Cboe UK - Cboe UK Real-time price. Currency in EUR
Add to watchlist
At close: 04:21PM BST
| Previous close | 88.41 |
| Open | 89.67 |
| Bid | 89.43 x 0 |
| Ask | 90.01 x 0 |
| Day's range | 89.67 - 89.69 |
| 52-week range | 80.89 - 104.24 |
| Volume | |
| Avg. volume | 471 |
| Market cap | 112.173B |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 24.85 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.76 (4.19%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
- Zacks
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
- Zacks
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.
- Fortune
Sanofi’s CEO is giving OpenAI access to its data in the hope of developing drugs more quickly
Sanofi CEO Paul Hudson thinks AI offers 'insane' potential for the pharmaceutical industry, which can spend up to $4 billion developing a drug.
© 2024 Yahoo. All rights reserved.